Overview

Efficacy and Safety Evaluating Study to Compare Uritos® (Imidafenacin) and Urotol® (Tolterodine) for Treatment of Overactive Bladder.

Status:
Completed

Trial end date:
2017-09-01

Target enrollment:

Participant gender:

Summary

Objective of this study was confirmation on non-inferiority and validation of similar safety profile of new anti-muscarinic medicinal product Uritos® (Imidafenacin) in comparison with other product from m-cholinergic antagonists group Urotol® (Tolterodine).

Phase:

Phase 3

Details

Lead Sponsor:

R-Pharm

Collaborator:

Synergy Research Inc.

Treatments:

Tolterodine Tartrate